Research programme: respiratory disorder therapies - Cordex Pharma

Drug Profile

Research programme: respiratory disorder therapies - Cordex Pharma

Alternative Names: chronic obstructive pulmonary disease therapeutics - Duska Therapeutics; Primastrene; respiratory disorder therapies research programme - Duska Therapeutics; Vagonixen

Latest Information Update: 20 Feb 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Duska Therapeutics
  • Class
  • Mechanism of Action Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease; Cough

Most Recent Events

  • 20 Feb 2009 Preclinical development is ongoing in USA
  • 31 Aug 2005 Preclinical trials in Asthma in USA (unspecified route)
  • 16 Feb 2005 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top